These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3211176)

  • 21. [Orally administered lisuride in the treatment of complex fluctuations of motion in Parkinson disease].
    Luquín MR; Obeso JA; Vaamonde J; Martínez Lage JM
    Neurologia; 1989 Sep; 4(7):229-32. PubMed ID: 2638588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
    Allain H; Destée A; Petit H; Patay M; Schück S; Bentué-Ferrer D; Le Cavorzin P
    Eur Neurol; 2000; 44(1):22-30. PubMed ID: 10894991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
    Agnoli A; Stocchi F; Carta A; Antonini A; Bragoni M; Ruggieri SA
    Mt Sinai J Med; 1988 Jan; 55(1):62-6. PubMed ID: 3258057
    [No Abstract]   [Full Text] [Related]  

  • 24. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous subcutaneous lisuride infusions in Parkinson's disease.
    Critchley PH; Grandas Perez F; Quinn NP; Parkes JD; Marsden CD
    J Neural Transm Suppl; 1988; 27():55-60. PubMed ID: 2969953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
    Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
    Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Randomized study during a year of early combination of L-dopa/lisuride in Parkinson disease].
    Vermersch P; Fondarai J; Petit H
    Therapie; 1991; 46(6):481-6. PubMed ID: 1819154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisuride combined with levodopa in advanced Parkinson disease.
    Lieberman AN; Goldstein M; Leibowitz M; Neophytides A; Gopinathan G; Walker R; Pact V
    Neurology; 1981 Nov; 31(11):1466-9. PubMed ID: 7031504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.
    Skalabrin EJ; Laws ER; Bennett JP
    Mov Disord; 1998 Sep; 13(5):775-81. PubMed ID: 9756145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
    Bergemann N; Baas H; Fischer PA
    Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One year treatment with lisuride delivery pump in Parkinson's disease.
    Ruggieri S; Stocchi F; Carta A; Bragoni M; Agostini C; Barbato L; Agnoli A
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):173-83. PubMed ID: 2748858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parenteral administration of lisuride in Parkinson's disease.
    Luquin MR; Obeso JA; Martínez-Lage JM; Tresguerres J; Parada J; Nieuweboer B; Dorow R; Horowski R
    Adv Neurol; 1987; 45():561-8. PubMed ID: 3825733
    [No Abstract]   [Full Text] [Related]  

  • 38. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
    Fuchs G
    Fortschr Med; 1997 Feb; 115(5):43-5. PubMed ID: 9162718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.